Plozalizumab

N/A

Report date: 2022/07/19 16:22:54

Base Information

Drug NamePlozalizumab
Drug Alias NameTAK-202MLN-1202
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionC-C chemokine receptor type 2 antagonists
TargetsC-C chemokine receptor type 2
Therapy Area/IndicationsSolid tumoursAtherosclerosisCardiovascular Diseases +[7
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesJapan
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesMillennium Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Active IndicationsN/A
Inactive IndicationsSolid tumoursAtherosclerosisCardiovascular Diseases +[7

Other Information

ATC CodeN/A
Related LinksWikipedia